Prior authorization and clopidogrel use - The truth lies in the details

Journal of Managed Care Pharmacy

Volumn 15, Issue 1, 2009, Pages 71-77

  Jackson, Mark A ^a   Fairman, Kathleen A ^b   Curtiss, Frederic R ^b  

^a Green Shield of Canada   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ACUTE CORONARY SYNDROME; ARTERY THROMBOSIS; CLINICAL TRIAL; CORONARY STENT; DRUG COST; DRUG ELUTING STENT; DRUG INDICATION; DRUG UTILIZATION; EDITORIAL; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MEDICARE; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIVATE HEALTH INSURANCE; REIMBURSEMENT;

EID: 59849116741     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.1.71     Document Type: Editorial

References (50)

1. Jackevicius CA, Tu JV, Demers V. Cardiovascular outcomes after a change in prescription policy for clopidogrel. N Engl J Med. 2008;359(17):1802-10.
2. World Health Organization. World Data Table. The Atlas of Heart Disease and Stroke. Available at: www.who.int/cardiovascular_diseases/en/cvd_atlas_29_world_data_table.pdf. Accessed December 1, 2008.
3. Peck P. Easing access to antiplatelet drugs improved coronary stem outcomes. MedPage Today. October 22, 2008. Available at: www.medpagetoday.com/Cardiology/PCI/11420. Accessed November 19, 2008.
4. Anonymous. Policy change improves cardiovascular outcomes: Canadian removal of prior-authorization policy for clopidogrel beneficial to heart attack patients. Modern Medicine. October 22, 2008. Available at: www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/ Policy-Change-Improves-Cardiovascular-Outcomes/ArticleNewsFeed/Article/ detail/560649. Accessed November 19, 2008.
5. Public Affairs Department, Western University of the Health Sciences. Faster medication = fewer heart attacks, according to a new study published today in the New England Journal of Medicine. October 23, 2008. Available at: www.wsprod.westernu.edu/news/ nr_detail.jsp?id=6282&groupname-AllNews. Accessed November 19, 2008.
6. Cox C. Policy changes leads to better clopidogrel access, improved outcomes. Tctmd: The Source for Interventional Cardiovascular News and Education. Available at: www.tctmd.com/show.aspx?id=74846. Accessed November 19, 2008.
7. Fairman KA, Curtiss FR. Making the world safe for evidence-based policy: let's slay the biases in research on value-based insurance design, J Manag Care Pharm. 2008;14(2):198-204. Available at: www.amcp.org/ data/jmcp/JMCPMaga_March%2008_198-204.pdf.
8. Ontario Ministry of Health and Long Term Care. Ontario Drug Benefit Formulary/Comparative Drug Index, Edition No. 38. Available at: www.health.gov.on.ca/english/providers/program/drugs/formulary_38/ ed38_0_bk.pdf. Accessed November 17, 2008.
9. Ontario Ministry of Health and Long Term Care. Ontario Drug Benefit Formulary/Comparative Drug Index, Edition No. 39. Available at: www.health.gov.on.ca/english/providers/program/drugs/formulary_39/ ed39_0_bk.pdf. Accessed November 25, 2008.
10. Ontario Ministry of Health and Long Term Care. 2003/2004 Report Card for the Ontario Drug Benefit Program. Available at: www.health.gov.on.ca/ english/public/pub/ministry_reports/odb_report03/drug_rep.html. Accessed November 17, 2008.
11. Ontario Ministry of Health and Long Term Care. 2001/2002 Report Card for the Ontario Drug Benefit Program. Available at: www.healthgov.on.ca/ english/providers/pub/drugs/odb_reports/odb_rep_01_02.pdf. Accessed December 3, 2008.
12. State of Maine Department of Health and Human Services Maine Care/ MEDEL. Prior Authorization Form: Plavix. Available at: www.mainecarepdl.org/index.pl/pafiles/pa---prior-authorization-forms/ plavix.20715.1.doc. Accessed November 19, 2008.
13. State of Pennsylvania Department of Public Welfare. Pharmacy prior authorization general requirements. Available at: www.dpw.state.pa.us/ PartnersProviders/MedicalAssistance/DoingBusiness/MAPharmProg/ 003675357.htm. Accessed November 19, 2008.
14. CIGNA Pharmacy Services. CIGNA HealthCare Medication Prior Authorization Form. Available at: www.cigna.com/health/provider/medical/forms/ 4_AZ¶∀rm.pdf. Accessed November 19, 2008.
15. HealthSpring Formulary Exception/Drug Prior Authorization Form: Revised 8.23.06. Available at: www.healthspring.com/userfiles/PharmacyContent/ HSNATMEM371%20PA%20Form.pdf.Accessed November 19, 2008.
16. Oklahoma Health Care Authority. Prior Authorization. Available at: www.ohca.state.ok.us/providers.aspx?id<1218. Accessed November 19, 2008.
17. Scan Health Plan Express Scripts, Inc. Prior Authorization Request Form. Available at: www.scanhealthplan.com/documents/arizona/ prior_auth_pharmacy_enu.pdf. Accessed November 19, 2008.
18. Phillips CR, Larson LN. Evaluating the operational performance and financial effects of a drug prior authorization program. J Manag Care Pharm. 1997;3(6):699-706. Available at: www.amcp.org/data/jmcp/ research_v6_699-706.pdf.
19. Ontario Ministry of Health and Long Term Care. Ontario Drug Benefit Formulary/Comparative Drug Index, Edition No. 38, Update B effective September 4, 2003. Available at; www.health.gov.on.ca/english/providers/ program/drugs/formulary_38/38_b_ven_final.xls. Accessed November 17, 2003.
20. Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? CMAJ. 2002;166(1):44-47.
21. Ontario Ministry of Health and Long Term Care. Request for Plavix (clopidogrel) Individual Clinical Review (Section 8). Form 4253-87. Available at: www.uwo.ca/cns/resident/tools/Section%208.pdf. Accessed November 29, 2008.
22. Ontario Ministry of Health and Long Term Care. Ontario Drug Benefit Formulary/Comparative Drug Index, Edition No. 40. Available at: www.health.gov.on.ca/english/providers/program/drugs/formulary_40/ edition_40.pdf. Accessed November 17, 2008.
23. Ontario Ministry of Health and Long Term Care. Publicly Funded Drug Programs. Available at: www.health.gov.on.ca/english/providers/program/ drugs/fundedℝug/fund_trillium.html. Accessed December 4, 2008.
24. Paterson JM, Suleiman A, Hux JE, Bell C. How complete are drug history profiles that are based on public drug benefit claims? Can J Clin Pharmacol. 2008; 15(1):e108-16.
25. Personal communication with J. Michael Paterson, Institute for Clinical Evaluative Sciences, Toronto, ON. November 24, 2008.
26. Cook TD, Campbell DT. Quasi-Experimentation: Design and Analysis Issues for Field Settings. Boston: Houghton Mifflin Company; 1979. pp 209-14.
27. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stems m Ontario. N Engl J Med. 2007;357(14):1393-402. Available at: www.content.nejm.org/cgi/reprint/357/14/1393.pdf. Accessed November 29, 2008.
28. et al. Drug eluting stents: an economic evaluation [Technology overview no 15]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; February 2005. Available at: www.cadth.ca/media/ pdf/372ℝugℓuting§ents_ov_e.pdf. Accessed November 29, 2008.
29. Supplementary Appendix. Supplement to: Tu JV, Bowen J, Chieu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357(14):1393-402. Available at: www.content.nejm.org/cgi/ data/357/14/1393/DC1/1. Accessed November 29, 2008.
30. Data reported by Solucient (Thomson Healthcare, Ann Arbor, Michigan) show that there were 1,400 drug-eluting stents of 55,800 total stent procedures (2.5%) in April 2003 and 33,400 of 60,800 total stent procedures (54.9%) in December 2003. Anonymous. By the numbers. Modern Healthcare. March 8, 2004:9.
31. Love MP, Schampaert E, Cohen EA, et al. The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents. Can J Cardiol. 2007;23(2):121-23. Available at www.ccs.ca/download/ position_statements/2007_10095_love.pdf. Accessed December 2, 2008.
32. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med. 2006;119(2):113-16.
33. Glassman AH, Bigger, JT Jr. Antidepressants in coronary heart disease: SSRIs reduce depression, but do they save lives? JAMA. 2007;297(4):411-12.
34. Taylor CB, Youngblood ME, Cartellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2003;62(7):792-98. Available at: www.archpsyc.ama-assn∨g/cgi/reprint/62/7/792. Accessed November 29, 2008.
35. Lange RA, Hillis DH. Antiplatelet therapy for ischemic heart disease. N Engl J Med. 2004;350(3):277-80.
36. Bayer Low Dose (81 mg enteric-coated) aspirin. $10.99 per 200 tablets at www.drugstore.com. Accessed November 30, 2008.
37. Discounted allowed charge before member cost share. Summary analysis of actual claims data for a large employer for the 3-month period of claims data through September 30, 2008.
38. Anonymous. Clopidogrel (Plavix) revisited. The Medical Letter. 2006;48(1232):29-31.
39. Gleason PP. Assessing step-therapy programs: a step in the right direction. J Manag Care Pharm. 2007;13(3):273-75. Available at: www.amcp.org/data/jmcp/273-75.pdf.
40. Curtiss FR. Outcomes of sword swallowing and pharmaceutical step-therapy interventions. J Manag Care Pharm. 2007;13(3):294-96. Available at: www.amcp.org/data/jmcp/284-86.pdf.
41. Mamdani M, Warren L, Kopp A, et al. Changes in rates of upper gastro-intestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario. CMAJ. 2006;175(12):1535-38. Available at: www.cmaj.ca/cgi/content/full/175/12/ 1535. Accessed November 18, 2008.
42. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372(9651):1756-64.
43. Choudhry NK, Levin R, Avorn J. The economic consequences of nonevidence-based clopidogrel use. Am Heart J. 2008;155(5):904-09.
44. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-17.
45. Wang TH, Bhatt DL, Fox KAA, et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J. 2007;28(18):2200-07.
46. Hoadley J, Hargrave E, Cubanski J, Neuman T. The Medicare Part D coverage gap: costs and consequences in 2007. Kaiser Family Foundation. Available at: www.kff.org/medicare/upload/7811.pdf. Accessed November 22, 2008.
47. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J. Med. 2007;357(7):673-81. Available at: www.content.nejm.org/cgi/content/full/ 357/7/673. Accessed November 22, 2008.
48. Anonymous. Top 200 brand drugs by retail dollars in 2007. Data from Verispan VONA. Drug Topics. March 10, 2008:28.
49. Anonymous. Top 200 brand drugs by retail dollars in 2002. Data from Verispan Scott-Levin SPA. Drug Topics. April 7, 2003.
50. Goldstein J. Lilly dubs would-be Plavix rival "Effient" Wall Street J. January 4, 2008. Available at: www.blogs.wsj.com/ health/2008/01/04/lilly-dubs-would-be-plavix-rival-effient/. Accessed November 22, 2008.